Total Payments
$1.2M
2024 Payments
$182,518
Companies
29
Transactions
377
Payment Breakdown by Category
Consulting$795,964 (64.5%)
Research$407,628 (33.0%)
Travel$20,294 (1.6%)
Other$6,514 (0.5%)
Food & Beverage$3,536 (0.3%)
Education$57.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $795,964 | 164 | 64.5% |
| Unspecified | $407,628 | 105 | 33.0% |
| Travel and Lodging | $20,294 | 37 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,514 | 2 | 0.4% |
| Food and Beverage | $3,536 | 66 | 0.3% |
| Honoraria | $2,000 | 1 | 0.2% |
| Education | $57.26 | 2 | 0.0% |
Payments by Type
General
$826,365
272 transactions
Research
$407,628
105 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $314,505 | 110 | $0 (2024) |
| Amgen Inc. | $206,835 | 24 | $0 (2023) |
| EMD Serono Research & Development Institute, Inc. | $166,950 | 12 | $0 (2024) |
| Celgene Corporation | $103,177 | 27 | $0 (2024) |
| SANOFI US SERVICES INC. | $101,019 | 16 | $0 (2023) |
| Merck Sharp & Dohme LLC | $67,785 | 43 | $0 (2024) |
| EMD Serono, Inc. | $64,693 | 10 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $58,719 | 49 | $0 (2024) |
| UCB SA | $36,441 | 9 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $26,481 | 10 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $182,518 | 50 | EMD Serono Research & Development Institute, Inc. ($77,625) |
| 2023 | $348,936 | 99 | Amgen Inc. ($99,000) |
| 2022 | $148,093 | 28 | ABBVIE INC. ($73,600) |
| 2021 | $201,620 | 27 | AbbVie Inc. ($87,250) |
| 2020 | $156,032 | 33 | AbbVie Inc. ($58,509) |
| 2019 | $93,508 | 61 | Celgene Corporation ($29,750) |
| 2018 | $67,437 | 35 | Celgene Corporation ($27,508) |
| 2017 | $35,848 | 44 | SANOFI-AVENTIS U.S. LLC ($9,893) |
All Payment Transactions
377 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $7,905.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 11/22/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 11/15/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $120.67 | General |
| 11/15/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $24.00 | General |
| 11/15/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $7.74 | General |
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,185.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $565.75 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 10/31/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Immunology | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $465.00 | General |
| 10/18/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Consulting Fee | Cash or cash equivalent | $8,550.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $465.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | EMD Serono Research & Development Institute, Inc. | — | — | Cash or cash equivalent | $9,900.00 | Research |
| Study: A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus Participants Receiving Standard of Care | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $697.50 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $465.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/23/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| 08/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $9,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 08/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 08/12/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,845.55 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus Participants Receiving Standard of Care | EMD Serono Research & Development Institute, Inc. | $110,925 | 8 |
| A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus | ABBVIE INC. | $86,250 | 7 |
| A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) | ABBVIE INC. | $73,000 | 5 |
| M19-130 | AbbVie Inc. | $48,480 | 9 |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | AbbVie Inc. | $35,402 | 39 |
| M16-063 | AbbVie, Inc. | $18,602 | 11 |
| Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | SANOFI US SERVICES INC. | $15,096 | 5 |
| M16-063 | AbbVie Inc. | $10,029 | 4 |
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus Participants Receiving Standard of Care | EMD Serono, Inc. | $4,500 | 1 |
| M19-130 | AbbVie, Inc. | $4,493 | 14 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | Celgene Corporation | $150.00 | 1 |
About Dr. Joan Merrill, MD
Dr. Joan Merrill, MD is a Rheumatology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962471813.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joan Merrill, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $182,518 received in 2024. These payments were reported across 377 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($795,964).
Ad
Practice Information
- Specialty Rheumatology
- Location Oklahoma City, OK
- Active Since 03/14/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1962471813
Products in Payments
- RINVOQ (Biological) $63,002
- Sotyktu (Drug) $21,375
- NO PRODUCT DISCUSSED (Drug) $11,928
- STELARA (Biological) $8,462
- BENLYSTA (Biological) $8,364
- CC-220 (Drug) $6,508
- ORENCIA (Biological) $5,802
- LUPKYNIS (Drug) $2,000
- Atacicept (Biological) $1,575
- Actemra (Biological) $1,539
- Ultomiris (Drug) $840.00
- SYNAGIS (Biological) $361.88
- Enbrel (Biological) $301.78
- XELJANZ (Drug) $230.96
- KEVZARA (Drug) $64.46
- TREMFYA (Drug) $54.99
- HUMIRA (Biological) $15.12
- TALTZ (Drug) $10.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Oklahoma City
Mrs. Latisha Heinlen, Md, MD
Rheumatology — Payments: $643,218
Rheumatology $643,218
Dr. Christine Codding, Md, MD
Rheumatology — Payments: $169,244
Rheumatology $169,244
Robert Arthur, Md, MD
Rheumatology — Payments: $21,751
Rheumatology $21,751
Judith James, Md, Phd, MD, PHD
Rheumatology — Payments: $20,697
Rheumatology $20,697
Muhammad Gillan, Md, MD
Rheumatology — Payments: $18,433
Rheumatology $18,433
Amanda Titus, Md, MD
Rheumatology — Payments: $11,993
Rheumatology $11,993